(
a) EPSC amplitudes did not increase after application of either N-arachidonyl maleimide (NAM) (150 nM. n = 7) or JZL184 (100 nM, n = 7), two selective inhibitors of monoacylglycerol lipase (MAGL), the 2-AG degrading enzyme, suggesting AEA rather than 2-AG is the endogenous ligand for this effect. (
b) EPSC amplitude increase induced by the CB1R agonist WIN 55,212-2 (n = 11) is blocked by the inverse agonist AM-251 (n = 7). It is not blocked by the GABAAR antagonist gabazine (n = 10), but is blocked by the GlyR antagonist strychnine (n = 6), Application of the NKCC1 inhibitor bumetanide (n = 5) also prevents the increase. (
c,
d) CB1R-IR is present in cell somata and retinorecipient neuropil of the optic tectum. DAPI (left) and CB1R-IR (right). Dashed lines delineate cell body layer and neuropil regions. (
e) Holding current and (
f) input resistance were not significantly different before (black) and after (grey) WIN 55,212-2 application. (
g) WIN 55,212-2 (n = 6) or URB597 (n = 7) application did not significantly change paired-pulse ratios but (
h) did induce an increase in CV
−2 (n = 14, WIN 55,212-2, p<0.01, one-sample t-test). A similar trend was observed in response to URB597 (n = 7) application. Because CV
−2 reflects the product of the number of release sites and the probability of release, a change in CV
−2 in the absence of any change in PPR is more consistent with an increase in the number of evoked release sites or recruitment of additional inputs than with a change in P
r at individual synapses (
Shirke and Malinow, 1997). *p<0.05; ***p<0.001 two-way RM ANOVA with Holm-Sidak posttest. AEA, anandamide; EPSC, Excitatory postsynaptic current.